M. Kloess

发表

NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity

M. Pfreundschuh, M. Loeffler, H. Bickeböller, 2005, Circulation.

of the NHL-B2 trial of the DSHNHL the Treatment of Elderly Patients with Aggressive Lymphomas: Results 2-weekly or 3-weekly CHOP Chemotherapy with or without Etoposide for

N. Schmitz, A. Feller, M. Reiser, 2013 .

aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL for the treatment of young patients with good-prognosis (normal LDH) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide

N. Schmitz, M. Pfreundschuh, D. Hasenclever, 2008 .

Four versus six courses of a dose‐escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation

M. Pfreundschuh, M. Loeffler, W. Berdel, 2006, Cancer.

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2006, Blood.

Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2005 .

Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

M. Pfreundschuh, M. Loeffler, M. Reiser, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

Dirk Hasenclever, Markus Loeffler, Christian Rübe, 2004, Blood.

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Dirk Hasenclever, Markus Loeffler, Christian Rübe, 2004, Blood.

Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia12

Sandra Siegel, Norbert Schmitz, N. Schmitz, 2008, The Journal of Immunology.

Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia 1 , 2

N. Schmitz, M. Tiemann, D. Kabelitz, 2008 .

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose Escalated CHOP + Etoposide Followed by Repetitive Autologous Stem Cell Transplantation (MegaCHOEP) with or without Rituximab for Primary Treatment of Aggressive NHL.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2005 .

Repetitive high-dose therapy followed by autologous stem cell transplantation (megachoep) for primary treatment of aggressive Nhl: the impact of rituximab on outcome and toxicity

N. Schmitz, L. Trümper, B. Metzner, 2006 .

2-weekly vs 3-weekly CHOP with and without Etoposide in Young Patients with Low-Risk Aggressive Non-Hodgkins Lymphoma Results of the Completed NHL-B-1 Trial of the DSHNHL

N. Schmitz, M. Pfreundschuh, L. Truemper, 2002 .

Potential of chromosomal and matrix-based comparative genomic hybridization for molecular diagnostics in lymphomas

H. Döhner, P. Lichter, M. Baudis, 2001, Annals of Hematology.

CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1): Feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin's Lymphoma Group DSHNHL.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Six vs. Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Completed RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2006 .

Dose escalated CHOP + etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2005 .

aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL for the treatment of young patients with good-prognosis (normal LDH) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide

N. Schmitz, M. Pfreundschuh, D. Hasenclever, 2008 .